Personal Products & Services
Compare Stocks
5 / 10Stock Comparison
MED vs RVLV vs AMZN vs HIMS vs GOOGL
Revenue, margins, valuation, and 5-year total return — side by side.
Specialty Retail
Specialty Retail
Medical - Equipment & Services
Internet Content & Information
MED vs RVLV vs AMZN vs HIMS vs GOOGL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Personal Products & Services | Specialty Retail | Specialty Retail | Medical - Equipment & Services | Internet Content & Information |
| Market Cap | $141M | $1.44B | $2.92T | $6.63B | $4.81T |
| Revenue (TTM) | $346M | $1.27B | $742.78B | $2.35B | $422.57B |
| Net Income (TTM) | $-20M | $64M | $90.80B | $128M | $160.21B |
| Gross Margin | 70.1% | 53.6% | 50.6% | 69.7% | 60.4% |
| Operating Margin | -4.7% | 5.9% | 11.5% | 4.6% | 32.7% |
| Forward P/E | — | 23.0x | 34.8x | 51.5x | 29.6x |
| Total Debt | $17M | $32M | $152.99B | $1.12B | $59.29B |
| Cash & Equiv. | $89M | $292M | $86.81B | $229M | $30.71B |
MED vs RVLV vs AMZN vs HIMS vs GOOGL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Medifast, Inc. (MED) | 100 | 12.3 | -87.7% |
| Revolve Group, Inc. (RVLV) | 100 | 148.4 | +48.4% |
| Amazon.com, Inc. (AMZN) | 100 | 223.3 | +123.3% |
| Hims & Hers Health,… (HIMS) | 100 | 284.6 | +184.6% |
| Alphabet Inc. (GOOGL) | 100 | 559.0 | +459.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MED vs RVLV vs AMZN vs HIMS vs GOOGL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
MED is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.
- Lower volatility, beta 0.94, Low D/E 8.4%, current ratio 4.69x
- Beta 0.94, yield 0.1%, current ratio 4.69x
- Beta 0.94 vs HIMS's 2.40, lower leverage
RVLV ranks third and is worth considering specifically for value.
- Lower P/E (23.0x vs 51.5x)
Among these 5 stocks, AMZN doesn't own a clear edge in any measured category.
HIMS is the clearest fit if your priority is growth.
- 59.0% revenue growth vs MED's -36.0%
GOOGL carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 2 yrs, beta 1.26, yield 0.2%
- Rev growth 15.1%, EPS growth 34.5%, 3Y rev CAGR 12.5%
- 10.0% 10Y total return vs AMZN's 7.0%
- PEG 0.99 vs RVLV's 13.45
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 59.0% revenue growth vs MED's -36.0% | |
| Value | Lower P/E (23.0x vs 51.5x) | |
| Quality / Margins | 37.9% margin vs MED's -5.8% | |
| Stability / Safety | Beta 0.94 vs HIMS's 2.40, lower leverage | |
| Dividends | 0.2% yield, 2-year raise streak, vs MED's 0.1%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +163.5% vs HIMS's -51.0% | |
| Efficiency (ROA) | 27.4% ROA vs MED's -7.7%, ROIC 25.1% vs -8.1% |
MED vs RVLV vs AMZN vs HIMS vs GOOGL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
MED vs RVLV vs AMZN vs HIMS vs GOOGL — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
GOOGL leads in 4 of 6 categories
MED leads 0 • RVLV leads 0 • AMZN leads 0 • HIMS leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
GOOGL leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
AMZN is the larger business by revenue, generating $742.8B annually — 2146.1x MED's $346M. GOOGL is the more profitable business, keeping 37.9% of every revenue dollar as net income compared to MED's -5.8%. On growth, HIMS holds the edge at +28.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $346M | $1.3B | $742.8B | $2.3B | $422.6B |
| EBITDAEarnings before interest/tax | -$5M | $79M | $155.9B | $164M | $161.3B |
| Net IncomeAfter-tax profit | -$20M | $64M | $90.8B | $128M | $160.2B |
| Free Cash FlowCash after capex | -$1M | $47M | -$2.5B | $73M | $73.3B |
| Gross MarginGross profit ÷ Revenue | +70.1% | +53.6% | +50.6% | +69.7% | +60.4% |
| Operating MarginEBIT ÷ Revenue | -4.7% | +5.9% | +11.5% | +4.6% | +32.7% |
| Net MarginNet income ÷ Revenue | -5.8% | +5.1% | +12.2% | +5.5% | +37.9% |
| FCF MarginFCF ÷ Revenue | -0.4% | +3.7% | -0.3% | +3.1% | +17.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | -34.3% | +15.6% | +16.6% | +28.4% | +21.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -171.4% | +25.0% | +74.8% | -27.3% | +81.9% |
Valuation Metrics
Evenly matched — MED and RVLV each lead in 3 of 7 comparable metrics.
Valuation Metrics
At 23.5x trailing earnings, RVLV trades at a 53% valuation discount to HIMS's 50.3x P/E. Adjusting for growth (PEG ratio), GOOGL offers better value at 1.23x vs RVLV's 13.74x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $141M | $1.4B | $2.92T | $6.6B | $4.81T |
| Enterprise ValueMkt cap + debt − cash | $69M | $1.2B | $2.98T | $7.5B | $4.84T |
| Trailing P/EPrice ÷ TTM EPS | -7.46x | 23.52x | 37.82x | 50.32x | 36.82x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 23.03x | 34.77x | 51.51x | 29.61x |
| PEG RatioP/E ÷ EPS growth rate | — | 13.74x | 1.35x | — | 1.23x |
| EV / EBITDAEnterprise value multiple | — | 15.01x | 20.47x | 42.68x | 32.22x |
| Price / SalesMarket cap ÷ Revenue | 0.37x | 1.18x | 4.07x | 2.82x | 11.95x |
| Price / BookPrice ÷ Book value/share | 0.70x | 2.85x | 7.14x | 12.25x | 11.72x |
| Price / FCFMarket cap ÷ FCF | 112.97x | 30.08x | 378.98x | 89.61x | 65.72x |
Profitability & Efficiency
GOOGL leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
GOOGL delivers a 39.0% return on equity — every $100 of shareholder capital generates $39 in annual profit, vs $-10 for MED. RVLV carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to HIMS's 2.07x. On the Piotroski fundamental quality scale (0–9), GOOGL scores 7/9 vs MED's 3/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -9.7% | +12.8% | +23.3% | +23.7% | +39.0% |
| ROA (TTM)Return on assets | -7.7% | +8.4% | +11.5% | +6.0% | +27.4% |
| ROICReturn on invested capital | -8.1% | +23.5% | +14.7% | +10.7% | +25.1% |
| ROCEReturn on capital employed | -6.5% | +14.8% | +15.3% | +10.9% | +30.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 | 6 | 4 | 7 |
| Debt / EquityFinancial leverage | 0.08x | 0.06x | 0.37x | 2.07x | 0.14x |
| Net DebtTotal debt minus cash | -$73M | -$260M | $66.2B | $892M | $28.6B |
| Cash & Equiv.Liquid assets | $89M | $292M | $86.8B | $229M | $30.7B |
| Total DebtShort + long-term debt | $17M | $32M | $153.0B | $1.1B | $59.3B |
| Interest CoverageEBIT ÷ Interest expense | — | — | 39.96x | — | 392.15x |
Total Returns (Dividends Reinvested)
GOOGL leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GOOGL five years ago would be worth $33,982 today (with dividends reinvested), compared to $1,023 for MED. Over the past 12 months, GOOGL leads with a +163.5% total return vs HIMS's -51.0%. The 3-year compound annual growth rate (CAGR) favors GOOGL at 54.8% vs MED's -43.7% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +22.0% | -31.6% | +19.7% | -23.2% | +26.4% |
| 1-Year ReturnPast 12 months | -2.0% | +18.5% | +43.7% | -51.0% | +163.5% |
| 3-Year ReturnCumulative with dividends | -82.2% | +9.7% | +156.2% | +116.6% | +270.8% |
| 5-Year ReturnCumulative with dividends | -89.8% | -65.2% | +64.8% | +137.6% | +239.8% |
| 10-Year ReturnCumulative with dividends | +23.4% | -40.5% | +697.8% | +161.9% | +996.1% |
| CAGR (3Y)Annualised 3-year return | -43.7% | +3.1% | +36.8% | +29.4% | +54.8% |
Risk & Volatility
Evenly matched — MED and GOOGL each lead in 1 of 2 comparable metrics.
Risk & Volatility
MED is the less volatile stock with a 0.94 beta — it tends to amplify market swings less than HIMS's 2.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GOOGL currently trades 99.5% from its 52-week high vs HIMS's 36.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.00x | 1.73x | 1.50x | 2.40x | 1.28x |
| 52-Week HighHighest price in past year | $15.46 | $31.68 | $278.56 | $70.43 | $400.10 |
| 52-Week LowLowest price in past year | $9.22 | $16.80 | $185.01 | $13.74 | $147.84 |
| % of 52W HighCurrent price vs 52-week peak | +82.1% | +63.9% | +97.3% | +36.4% | +99.5% |
| RSI (14)Momentum oscillator 0–100 | 71.5 | 26.7 | 81.1 | 54.5 | 83.4 |
| Avg Volume (50D)Average daily shares traded | 234K | 931K | 45.5M | 34.9M | 28.3M |
Analyst Outlook
GOOGL leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: MED as "Hold", RVLV as "Buy", AMZN as "Buy", HIMS as "Hold", GOOGL as "Buy". Consensus price targets imply 46.1% upside for RVLV (target: $30) vs -5.4% for MED (target: $12). For income investors, GOOGL offers the higher dividend yield at 0.21% vs MED's 0.14%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | $12.00 | $29.56 | $306.77 | $29.67 | $406.28 |
| # AnalystsCovering analysts | 12 | 30 | 94 | 19 | 82 |
| Dividend YieldAnnual dividend ÷ price | +0.1% | — | — | — | +0.2% |
| Dividend StreakConsecutive years of raises | 0 | — | — | — | 2 |
| Dividend / ShareAnnual DPS | $0.02 | — | — | — | $0.82 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.3% | +0.1% | 0.0% | +1.4% | +0.9% |
GOOGL leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
MED vs RVLV vs AMZN vs HIMS vs GOOGL: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is MED or RVLV or AMZN or HIMS or GOOGL a better buy right now?
For growth investors, Hims & Hers Health, Inc.
(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -36. 0% for Medifast, Inc. (MED). Revolve Group, Inc. (RVLV) offers the better valuation at 23. 5x trailing P/E (23. 0x forward), making it the more compelling value choice. Analysts rate Revolve Group, Inc. (RVLV) a "Buy" — based on 30 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MED or RVLV or AMZN or HIMS or GOOGL?
On trailing P/E, Revolve Group, Inc.
(RVLV) is the cheapest at 23. 5x versus Hims & Hers Health, Inc. at 50. 3x. On forward P/E, Revolve Group, Inc. is actually cheaper at 23. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Alphabet Inc. wins at 0. 99x versus Revolve Group, Inc. 's 13. 45x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — MED or RVLV or AMZN or HIMS or GOOGL?
Over the past 5 years, Alphabet Inc.
(GOOGL) delivered a total return of +239. 8%, compared to -89. 8% for Medifast, Inc. (MED). Over 10 years, the gap is even starker: GOOGL returned +1004% versus RVLV's -38. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MED or RVLV or AMZN or HIMS or GOOGL?
By beta (market sensitivity over 5 years), Medifast, Inc.
(MED) is the lower-risk stock at 1. 00β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 139% more volatile than MED relative to the S&P 500. On balance sheet safety, Revolve Group, Inc. (RVLV) carries a lower debt/equity ratio of 6% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — MED or RVLV or AMZN or HIMS or GOOGL?
By revenue growth (latest reported year), Hims & Hers Health, Inc.
(HIMS) is pulling ahead at 59. 0% versus -36. 0% for Medifast, Inc. (MED). On earnings-per-share growth, the picture is similar: Alphabet Inc. grew EPS 34. 5% year-over-year, compared to -994. 7% for Medifast, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MED or RVLV or AMZN or HIMS or GOOGL?
Alphabet Inc.
(GOOGL) is the more profitable company, earning 32. 8% net margin versus -4. 8% for Medifast, Inc. — meaning it keeps 32. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GOOGL leads at 32. 1% versus -3. 7% for MED. At the gross margin level — before operating expenses — MED leads at 71. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is MED or RVLV or AMZN or HIMS or GOOGL more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Alphabet Inc. (GOOGL) is the more undervalued stock at a PEG of 0. 99x versus Revolve Group, Inc. 's 13. 45x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Revolve Group, Inc. (RVLV) trades at 23. 0x forward P/E versus 51. 5x for Hims & Hers Health, Inc. — 28. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RVLV: 46. 1% to $29. 56.
08Which pays a better dividend — MED or RVLV or AMZN or HIMS or GOOGL?
In this comparison, GOOGL (0.
2% yield), MED (0. 1% yield) pay a dividend. RVLV, AMZN, HIMS do not pay a meaningful dividend and should not be held primarily for income.
09Is MED or RVLV or AMZN or HIMS or GOOGL better for a retirement portfolio?
For long-horizon retirement investors, Alphabet Inc.
(GOOGL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 28), +1004% 10Y return). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 40 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GOOGL: +1004%, HIMS: +161. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between MED and RVLV and AMZN and HIMS and GOOGL?
These companies operate in different sectors (MED (Consumer Cyclical) and RVLV (Consumer Cyclical) and AMZN (Consumer Cyclical) and HIMS (Healthcare) and GOOGL (Communication Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: MED is a small-cap quality compounder stock; RVLV is a small-cap quality compounder stock; AMZN is a mega-cap quality compounder stock; HIMS is a small-cap high-growth stock; GOOGL is a mega-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.